
Opinion|Videos|October 28, 2024
B7-H3 Mechanism and Therapeutic Potential
Author(s)Joshua K. Sabari, MD
Joshua K. Sabari, MD, discusses the unique mechanism of action of B7-H3, highlighting its role as an immune checkpoint regulator that is overexpressed in SCLC and associated with poor prognosis. He notes that B7-H3 blockade can enhance CD8-positive T-cell activity and may serve as a promising treatment option for SCLC that has progressed after platinum-based chemotherapy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Please discuss the unique mechanism of action of B7-H3 and its treatment potential as subsequent therapy for SCLC that has progressed after platinum-based chemotherapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5
















